Previous close $1.02
NICI Rating

Latest Updates on CRBP

Loading Chart...

Latest Trading on NASDAQ

Open 1.02
Previous Close 1.02
Today's Range
1.02 1.02
52 Week Range
0.91 4.00
Volume 1.26K
Avg. Volume (Weekly) 453.49K
Bid 1.02
Ask 1.03
Market Cap 127.74K
EPS -0.82
Shares Outstanding 125.23K
YTD High 4.00
Updated November 27, 2018

Corbus Pharmaceuticals Holdings Inc

Corbus Pharmaceuticals is a pharmaceutical company working on therapies for inflammatory and fibrotic diseases. They are in the clinical stage of drug development for a subset of drugs that interact with the endocannabinoid system – the system in our bodies that responds to compounds in cannabis like THC and CBD.

No data to display.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.